US economy slows to 1.6% in Q1 of '24 – BEA    EMX appoints Al-Jarawi as deputy chairman    Mexico's inflation exceeds expectations in 1st half of April    GAFI empowers entrepreneurs, startups in collaboration with African Development Bank    Egyptian exporters advocate for two-year tax exemption    Egyptian Prime Minister follows up on efforts to increase strategic reserves of essential commodities    Italy hits Amazon with a €10m fine over anti-competitive practices    Environment Ministry, Haretna Foundation sign protocol for sustainable development    After 200 days of war, our resolve stands unyielding, akin to might of mountains: Abu Ubaida    World Bank pauses $150m funding for Tanzanian tourism project    China's '40 coal cutback falls short, threatens climate    Swiss freeze on Russian assets dwindles to $6.36b in '23    Amir Karara reflects on 'Beit Al-Rifai' success, aspires for future collaborations    Ministers of Health, Education launch 'Partnership for Healthy Cities' initiative in schools    Egyptian President and Spanish PM discuss Middle East tensions, bilateral relations in phone call    Amstone Egypt unveils groundbreaking "Hydra B5" Patrol Boat, bolstering domestic defence production    Climate change risks 70% of global workforce – ILO    Health Ministry, EADP establish cooperation protocol for African initiatives    Prime Minister Madbouly reviews cooperation with South Sudan    Ramses II statue head returns to Egypt after repatriation from Switzerland    Egypt retains top spot in CFA's MENA Research Challenge    Egyptian public, private sectors off on Apr 25 marking Sinai Liberation    EU pledges €3.5b for oceans, environment    Egypt forms supreme committee to revive historic Ahl Al-Bayt Trail    Debt swaps could unlock $100b for climate action    Acts of goodness: Transforming companies, people, communities    President Al-Sisi embarks on new term with pledge for prosperity, democratic evolution    Amal Al Ghad Magazine congratulates President Sisi on new office term    Egypt starts construction of groundwater drinking water stations in South Sudan    Egyptian, Japanese Judo communities celebrate new coach at Tokyo's Embassy in Cairo    Uppingham Cairo and Rafa Nadal Academy Unite to Elevate Sports Education in Egypt with the Introduction of the "Rafa Nadal Tennis Program"    Financial literacy becomes extremely important – EGX official    Euro area annual inflation up to 2.9% – Eurostat    BYD، Brazil's Sigma Lithium JV likely    UNESCO celebrates World Arabic Language Day    Motaz Azaiza mural in Manchester tribute to Palestinian journalists    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Some Europeans get choosy about which vaccines they want
Published in Ahram Online on 13 - 02 - 2021

Many Europeans are desperate for a coronavirus vaccine. But not just any vaccine.
As AstraZeneca shots are rolling out to European Union nations this month, joining the Pfizer and Moderna doses already available, some people are balking at being offered a vaccine that they perceive — fairly or not — as second-best.
Poland began vaccinating teachers Friday with the AstraZeneca vaccine, and some had misgivings about being put in line for a vaccine they believe is less effective than the others.
Ewelina Jankowska, the director of a primary and high school in Warsaw's southern Wilanow district, said nobody in her school was enthusiastic about getting the AstraZeneca shot, although many signed up, eager for any protection against a virus that has upended their lives and their students' schooling.
“I still fear the illness more than the AstraZeneca vaccine,” said Jankowska, who was infected with COVID-19 in November and had a very slow recovery.
AstraZeneca, an Anglo-Swedish company, developed its vaccine with the University of Oxford. While regulators in more than 50 countries, including the EU's drug watchdog, have authorized its widespread use, it has attracted more criticism than others due to concerns about its human trials.
Several European nations have recommended the drug only for people under 65, and other countries have recommended it for those under 55, because AstraZeneca's trials included a relatively small number of older people.
AstraZeneca CEO Pascal Soriot acknowledged the criticism but said regulators had reviewed the data and deemed the vaccine safe and effective. COVID-19 vaccines are in short supply, he said, and the AstraZeneca shot offers high levels of protection against severe disease, which is the most important benchmark in fighting a virus that has killed more than 2.3 million people worldwide.
“Is it perfect? No, it's not perfect, but it's great,” Soriot said Thursday. “We're going to save thousands of lives and that's why we come to work every day.”
The World Health Organization says the AstraZeneca vaccine is about 63% effective at preventing symptomatic COVID-19 after two doses. That's less than the 95% effectiveness reported by Pfizer and Moderna, but experts caution against such comparisons as the studies were done at different times and under different conditions. Furthermore, all have proven extremely effective at preventing serious illness and death.
“If you're offered any approved vaccine, take it,” said Peter Piot, director of the London School of Hygiene and Tropical Medicine. “They have all been found safe. Vaccines are the world's route back to some sort of normality.”
French President Emmanuel Macron angered scientists last month when he called the AstraZeneca vaccine “quasi-ineffective” for people over 65 — a comment that came hours before the European Medicines Agency approved it and said it could be used for all adults, including those over 65. Those who criticized Macron argued that he had spoken irresponsibly and had encouraged vaccine skepticism.
French Health Minister Olivier Veran, who is 40, made a point this week of getting the AstraZeneca vaccine to show government confidence in it for under-65s.
Adding to AstraZeneca's troubles have been criticism from the EU about delivery shortages, its lack of approval yet in the U.S., and a preliminary study that raised questions about the vaccine's ability to combat a COVID-19 variant discovered in South Africa. In its favor, however, is that it is cheaper and can be stored at refrigerator temperatures — not the far colder temperatures required of the Pfizer and Moderna vaccines.
In Cyprus, Health Minister Constantinos Ioannou warned that opting for one over another risks delaying inoculations, given the limited deliveries of Pfizer and Moderna vaccines in the coming weeks, and he noted “all three vaccines reduce hospitalizations and deaths drastically.”
Yet in Poland, Spain and Italy, some unions complained that their members are slated to receive the AstraZeneca vaccine, expressing concerns they were being treated as less important than groups getting the Pfizer or Moderna doses.
Police unions in Spain have raised concerns about a government decision to administer AstraZeneca shots to police, military, firefighters and teachers.
Some Italian doctors in the private sector are declining AstraZeneca shots, saying they want the Pfizer or Moderna shots going to public health care workers.
“I'm not a no-vax AstraZeneca. But for an at-risk population, health care workers, they should use the same vaccination strategy for everyone and not create any discrimination,” said Dr. Paolo Mezzana, a Rome plastic surgeon who helps administer a Facebook group of private doctors. They have been posting refusals to accept the AstraZeneca shot after vaccinations began this week.
In Poland, the government announced earlier this month that the planned delivery of more than 1 million AstraZeneca doses meant teachers could get their shots ahead of schedule because the vaccine would not be given to older adults.
But instead of expressing relief, the head of the main teachers' union, Slawomir Broniarz, criticized the use of the vaccine in remarks that, in turn, came under fire from scientists and the government.
Michal Dworczyk, who leads the government's vaccine effort, said he regretted “that some irresponsible politicians or trade unions have tried to scare teachers or cause such anxiety by giving false information about the AstraZeneca vaccine.”
Yet a sense of misgiving has settled in among teachers, who already have been in conflict with the government for years over low wages and unpopular reforms.
Patrycja Swistowska, who teaches second grade at the Wilanow school, said she signed up for the AstraZeneca shot despite her fears and confusion.
“I feel that teachers are treated a bit worse and this is the vaccine that they offered us. They didn't offer us the vaccines given to doctors and other professional groups,” said Swistowska, 39. “I am disoriented and I don't feel good about this. We are paid worse and this is just another example of us being shown our place.“
In Italy, the head of the SAP police union, Stefano Paoloni, argued that if officers believe they are getting a less-effective vaccine via the police force, they can opt out and wait to get another shot later when the rest of the population is vaccinated. That would defeat the strategy to vaccinate as many at-risk people as quickly as possible.
Some unions are going ahead with the AstraZeneca rollout without complaining, reflecting gratitude to get any protection.
Dr. Arianna Patricarca, a 52-year-old Italian dentist who received the AstraZeneca shot Thursday, called it “a great opportunity and I am very happy that I did it.”
Warsaw preschool director Agnieszka Grabowska also welcomed getting the AstraZeneca vaccine Friday.
“It is a great relief,” said Grabowska, 48, adding that she was exhausted after a year of the pandemic.
“I have been waiting for this moment all year,” she said.


Clic here to read the story from its source.